Gentamycin sulfate
1.Basic information:
Molecular Formula:C21H43N5O7.H2SO4
Molecular Weight:575.67
EINECS:215-778-9
Melting Point:218-237
Boiling Point:797.6 at 760 mmHg
Flash Point:436.2
Risk CodesR42/43
2.Application:
Gentamycin sulfate (CAS NO.1405-41-0) can be used as biochemical reagent, for example in some medicine use, as the antibacterial medicine. And it can be the medicine for the treatment of sepsis, urinary tract infection, staphylococcus infection, endocarditis and other diseases. Main Ingredients: Gentamycin Sulfate Appearance: It is off-white or white powder. Pharmacological Action: It is anti-bacterial to gram-negative bacterium( such as Escherichia coli, Klebsiella, Bacillus aeruginosus, Pasteurella, salmonella etc) and Staphylococcus aureus. It has drug resistance to anaerobic bacterium, Mycobecterium Tuberculosis and epiphyte. On clinic Gentamycin drug-resistant strain is not all-pervading than that of streptomycin and kanamycin. Indications: It is mainly used to treat blood poisoning, respiratory disease, intestine and stomach infection( including peritonitis) mastitis due to gram-negative bacterium, such as Escherichia coli, salmonellosis, poultry typhoid fever and paratyphoid fever etc. Administration and Dosage: Dissolve 100g into 200kg water, during 3-5 days.
3.Specifications:
Toxicity Data With Reference
|
Organism
|
Test Type
|
Route
|
Reported Dose (Normalized Dose)
|
Effect
|
Source
|
|
guinea pig
|
LD50
|
subcutaneous
|
600mg/kg (600mg/kg)
|
|
Chemotherapy Vol. 16, Pg. 105, 1968.
|
|
man
|
TDLo
|
intravenous
|
21mg/kg/6D-I (21mg/kg)
|
|
Drug Intelligence and Clinical Pharmacy. Vol. 18, Pg. 596, 1984.
|
|
mouse
|
LD50
|
intracrebral
|
17300ug/kg (17.3mg/kg)
|
PERIPHERAL NERVE AND SENSATION: SENSORY CHANGE INVOLVING PERIPHERAL NERVE
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE |
Chemotherapy Vol. 15, Pg. 483, 1967.
|
|
mouse
|
LD50
|
intramuscular
|
250mg/kg (250mg/kg)
|
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION |
Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 8, Pg. 219, 1982.
|
|
mouse
|
LD50
|
intraperitoneal
|
245mg/kg (245mg/kg)
|
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD |
Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 8, Pg. 219, 1982.
|
|
mouse
|
LD50
|
intravenous
|
47mg/kg (47mg/kg)
|
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA |
Japanese Journal of Antibiotics. Vol. 39, Pg. 3164, 1986.
|
|
mouse
|
LD50
|
oral
|
> 11269mg/kg (11269mg/kg)
|
|
Drugs in Japan Vol. 6, Pg. 268, 1982.
|
|
mouse
|
LD50
|
subcutaneous
|
478mg/kg (478mg/kg)
|
|
Journal of Antibiotics. Vol. 23, Pg. 551, 1970.
|
|
rat
|
LD50
|
intramuscular
|
384mg/kg (384mg/kg)
|
|
Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971.
|
|
rat
|
LD50
|
intraperitoneal
|
630mg/kg (630mg/kg)
|
BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES |
Japanese Journal of Antibiotics. Vol. 26, Pg. 221, 1973.
|
|
rat
|
LD50
|
intravenous
|
96mg/kg (96mg/kg)
|
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION |
Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 8, Pg. 219, 1982.
|
|
rat
|
LD50
|
oral
|
> 5gm/kg (5000mg/kg)
|
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
SKIN AND APPENDAGES (SKIN): HAIR: OTHER |
Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 8, Pg. 219, 1982.
|
|
rat
|
LD50
|
subcutaneous
|
873mg(base)/k (873mg/kg)
|
|
Antibiotiki i Khimioterapiya. Antibiotics and Chemotherapy. Vol. 35(9), Pg. 26, 1990.
|
|
women
|
TDLo
|
intravenous
|
45mg/kg/1W-I (45mg/kg)
|
|
Drug Intelligence and Clinical Pharmacy. Vol. 18, Pg. 596, 1984.
|